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Abstract
 
Our laboratory has been testing the hypothesis that genetic
modulation of the 
 
b
 
-adrenergic signaling cascade can en-
hance cardiac function. We have previously shown that
transgenic mice with cardiac overexpression of either the
human 
 
b
 
2
 
-adrenergic receptor (
 
b
 
2
 
AR) or an inhibitor of the
 
b
 
-adrenergic receptor kinase (
 
b
 
ARK), an enzyme that
phosphorylates and uncouples agonist-bound receptors,
have increased myocardial inotropy. We now have created
recombinant adenoviruses encoding either the 
 
b
 
2
 
AR (Ad-
eno-
 
b
 
2
 
AR) or a peptide 
 
b
 
ARK inhibitor (consisting of the
carboxyl terminus of 
 
b
 
ARK1, Adeno-
 
b
 
ARKct) and tested
their ability to potentiate 
 
b
 
-adrenergic signaling in cultured
adult rabbit ventricular myocytes. As assessed by radioli-
gand binding, Adeno-
 
b
 
2
 
AR infection led to 
 
z
 
 20-fold over-
expression of 
 
b
 
-adrenergic receptors. Protein immunoblots
demonstrated the presence of the Adeno-
 
b
 
ARKct trans-
gene. Both transgenes significantly increased isoproterenol-
stimulated cAMP as compared to myocytes infected with an
adenovirus encoding 
 
b
 
-galactosidase (Adeno-
 
b
 
Gal) but did
not affect the sarcolemmal adenylyl cyclase response to For-
skolin or NaF. 
 
b
 
-Adrenergic agonist-induced desensitiza-
tion was significantly inhibited in Adeno-
 
b
 
ARKct–infected
myocytes (16
 
6
 
2%) as compared to Adeno-
 
b
 
Gal-infected
myocytes (37
 
6
 
1%, 
 
P 
 
,
 
 0.001). We conclude that recombi-
nant adenoviral gene transfer of the 
 
b
 
2
 
AR or an inhibitor of
 
b
 
ARK-mediated desensitization can potentiate 
 
b
 
-adrener-
gic signaling. (
 
J. Clin. Invest. 
 
1997. 99:288–296.) Key words:
gene therapy 
 
• 
 
b
 
-adrenergic receptor 
 
• 
 
myocardium 
 
• 
 
cul-
tured cells 
 
• 
 
congestive heart failure
 
Introduction
 
The activation of 
 
b
 
-adrenergic receptors (
 
b
 
-ARs)
 
1
 
 by cate-
cholamines is a critical event in the regulation of cardiac func-
tion. Transduction of this signal is mediated by heterotrimeric
guanine nucleotide binding (G) proteins and includes the gen-
eration of second messengers such as cAMP. In turn, cAMP-
dependent protein kinase (PKA) is activated and phosphory-
lates proteins including L-type voltage-dependent calcium
channels (1) and phospholamban (2), leading to enhanced car-
diac chronotropy and inotropy. Though the 
 
b
 
1
 
-AR is the pre-
dominant subtype present in the myocardium, 
 
z
 
 20–30% of
total cardiac 
 
b
 
-ARs are 
 
b
 
2
 
-ARs and they too contribute to the
regulation of cardiac function (3), possibly through a distinct
intracellular pathway (4, 5).
Congestive heart failure (CHF) is a clinical syndrome that
confers significant morbidity and mortality despite recent ad-
vances in medical therapy (6). Numerous abnormalities in the
 
b
 
-AR signaling cascade occur in this syndrome including a se-
lective downregulation of 
 
b
 
1
 
ARs (7, 8) and an upregulation of
the 
 
b
 
-adrenergic receptor kinase (
 
b
 
ARK), an enzyme that
specifically phosphorylates and uncouples the activated 
 
b
 
-AR
(9, 10). Modulation of this pathway to improve cardiac ino-
tropy is being explored by our laboratory as a novel therapeu-
tic approach for CHF. Transgenic mice with selective cardiac
overexpression of either the human 
 
b
 
2
 
AR (11) or an inhibitor
of 
 
b
 
ARK (12) have enhanced contractility. The current study
was undertaken to explore whether recombinant adenoviral-
mediated transfer of these transgenes would be able to poten-
tiate 
 
b
 
-adrenergic signaling in cultured adult rabbit ventricular
myocytes.
 
Methods
 
Myocyte isolation and culture. 
 
All studies with rabbits were ap-
proved by the institutional review board at Duke University. Adult
male New Zealand white rabbits were anesthetized, treated with hep-
arin, and then intubated. The heart was excised and perfused by the
Langendorff technique with Joklik’s modified MEM containing hy-
aluronidase, collagenase, protease, and 12.5 
 
m
 
M CaCl
 
2
 
 as previously
described in references 13 and 14. When the heart turned soft, the
ventricles were dissected free and agitated into a solution of Joklik’s
MEM with 10% fetal bovine serum. Cells were allowed to settle by
gravity twice in 10 ml of culture medium (medium 199 with Earle’s
salts, 25 mM Hepes, and sodium bicarbonate without glutamine
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1. 
 
Abbreviations used in this paper:
 
 Adeno-
 
b
 
2
 
AR, Adenovirus encod-
ing human 
 
b
 
2
 
-adrenergic receptor; Adeno-
 
b
 
ARKct, Adenovirus en-
coding 
 
b
 
ARK
 
ct
 
 transgene; Adeno-
 
b
 
Gal, Adenovirus encoding a
 
b
 
-galactosidase transgene; 
 
b
 
AR, 
 
b
 
-adrenergic receptor; 
 
b
 
ARK,
 
b
 
-adrenergic receptor kinase; 
 
b
 
ARKct, carboxyl terminus fragment
of bovine 
 
b
 
ARK1; CHF, congestive heart failure; CMV, cytomega-
lovirus; ISO, (
 
2
 
)-isoproterenol.
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[Sigma Chemical Co., St. Louis, MO] containing 10% fetal bovine se-
rum [GIBCO BRL, Gaithersburg, MD], 10 
 
m
 
M cytosine 
 
b
 
-D-arabino-
furanoside [ARA-C; Sigma Chemical Co.], 100 IU/ml penicillin, and
100 
 
m
 
g/ml streptomycin [Sigma Chemical Co.]). This procedure typi-
cally yielded 1–2 
 
3
 
 10
 
7
 
 myocytes per rabbit heart, with 50–80% in a
rod-shaped morphology. Myocytes were plated at a density of 1 
 
3
 
10
 
5
 
/35 mm well or 1 
 
3
 
 10
 
6
 
 100 mm well on tissue culture plates that
were precoated with 20 
 
m
 
g/ml of mouse laminin (GIBCO BRL) for 1 h.
The myocytes were calcium tolerant as evidenced by their quiescent
state throughout the experiments.
 
Adenoviral construction. 
 
Preparation of the 
 
b
 
-galactosidase ade-
novirus (Adeno-
 
b
 
Gal) (see Fig. 1) has been described in reference
15. The adenoviral backbone for Adeno-
 
b
 
2
 
AR and Adeno-
 
b
 
ARKct
was a replication-deficient “first-generation” adenovirus with dele-
tions of the E1 and E3 genes. It contains the cytomegalovirus (CMV)
promoter and bovine growth hormone polyadenylation (bGH) site
separated by a polylinker containing a unique XbaI site. The Adeno-
empty vector does not contain an insert in the polylinker region. 100
 
m
 
g of Adeno-empty vector DNA was prepared by digestion of a large
scale preparation of this virus (see below) with proteinase K (Sigma
Chemical Co.) in the presence of 0.5% SDS at 55
 
8
 
C for 2 h, followed
by phenol/chloroform (1:1 ratio) extraction and ethanol precipitation.
This was then digested by XbaI overnight and the large fragment con-
taining the bGH and adenovirus map units 9.3–100 was gel purified
on a 0.6% agarose gel. This fragment served as the “right end” of
both Adeno-
 
b
 
2
 
AR and Adeno-
 
b
 
ARKct. The “left ends” of these vi-
ruses were constructed uniquely. For Adeno-
 
b
 
2
 
AR, plasmid pCMV4
(16) was digested by SpeI and XbaI. The resulting 740-bp band was
subcloned into plasmid pACCMV (gift of Dr. Robert Gerard, Uni-
versity of Texas Southwestern Medical Center, Dallas, TX) creating
plasmid pACCMV4. The human 
 
b
 
2
 
AR (11) was PCR amplified using
primers 5
 
9
 
-AATTGAATTCCCAGACTGCGCGCCATGG-3
 
9
 
 and
5
 
9
 
-ATATTCTAGATGCAGGTGGACTGCTACC-3
 
9
 
, digested with
EcoRI and XbaI, and then subcloned into plasmid pACCMV4. This
construct was then digested with PvuI and XbaI and the fragment
(Adeno-
 
b
 
2
 
AR “left end”) containing adenovirus map units 0.0–1.3,
the CMV promoter, the AMV translational enhancer derived from
plasmid pCMV4, and the human 
 
b
 
2
 
AR was gel purified. For the “left
end” of Adeno-
 
b
 
ARKct, plasmid pACCMV4 was PCR amplified
with primers 5
 
9
 
-AATGCCGGCGTTTAAACATCATCAATAAT-
ATACC-3
 
9
 
 and 5
 
9
 
-AATTCTAGATTAATTAAGCTAGCCTAG-
GATCCCCGGGTACCGAG-3
 
9
 
, digested with NgoMI and XbaI,
and subcloned into plasmid pBluescript SK (Strategene, La Jolla,
CA) creating plasmid pSKAC. The 
 
b
 
ARK1 carboxyl terminus frag-
ment (
 
b
 
ARKct; 17) was digested with EcoRI and XbaI and sub-
cloned into pSKAC. The resulting construct was digested with PmeI
and XbaI, and the fragment (Adeno-
 
b
 
ARKct “left end”) containing
adenovirus map units 0.0–1.3, the CMV promoter, the AMV transla-
tional enhancer, and 
 
b
 
ARKct was gel purified. Approximately 100 ng
of the appropriate gel-purified “left end” fragment of Adeno-
 
b
 
2
 
AR
or Adeno-
 
b
 
ARKct was then ligated to 
 
z
 
 1 
 
m
 
g of the “right end” frag-
ment overnight at 16
 
8
 
C. The ligation mixture was transfected onto a
single 60 mm dish of 293 human embryonal kidney cells (18) using li-
pofectamine (GIBCO BRL). The plate was allowed to lyse without
an agar overlay. Individual viruses were then isolated by two consecu-
tive rounds of plaque purification using an agar overlay.
After isolation, individual viruses were prepared at large scale by
infecting 40 150 mm plates of EBNA transfected 293 cells (Invitrogen
Corp., San Diego, CA) with the appropriate virus at a multiplicity of
infection (moi) of three. 36–48 h after infection, when the majority of
the cells were floating, the cells were harvested by gentle scraping and
collected by a 5 min centrifugation at 1,000 
 
g
 
 in a GSA rotor. The cell
pellet was resuspended in 20 mM Tris HCl, pH 7.4, 2 mM EDTA, pH
8.0, and the cells were homogenized with 20 strokes in a Dounce ho-
mogenizer. DNase A was added to 100 
 
m
 
g/ml and the homogenate
was incubated at room temperature for 5 min. The nuclei were re-
moved by centrifugation at 2,500 
 
g
 
 for 10 min. CsCl was added to the
supernatant to 0.3 g/ml and the supernatant was then layered on top
of a CsCl step gradient (1.3 and 1.4 g/ml prepared in virus storage
buffer [VSB] 137 mM NaCl, 20 mM Tris HCl, pH 7.4, 5 mM KCl, and
1 mM MgCl
 
2
 
) and centrifuged for 2 h at 32K rpm in a Sorvall Instru-
ments Div. (Newton, CT) TH 64 rotor. The virus band that formed at
the 1.3–1.4 g/ml interphase was removed with a 16 gauge needle. The
virus preparation was layered on top of a 2 ml bed of Cl-6B (Pharma-
cia Fine Chemicals, Piscataway, NJ) prepared in a 3 ml syringe and
centrifuged for 2 min at 1,000 rpm in a Beckman Instruments, Inc.
(Fullerton, CA) tabletop centrifuge. This step was repeated once
more and the virus concentration was adjusted to 1 
 
3
 
 10
 
11
 
 plaque
forming units (pfu)/ml in VSB. Sucrose was added to 10% final and
the virus preparation was stored in aliquots at 
 
2
 
80
 
8
 
C. Each aliquot
was used a maximum of two times and discarded. Adenoviral titers
were determined using plaque titration on HEK 293 cells (17). Alter-
natively, plaque titers were estimated by determining the absorbance
at 260 nm (pfu/ml 5 A260 3 dilution 3 10
10) of the final viral prepara-
tion.
Adenoviral infection. After myocytes became adherent to the
tissue culture plates (z 5 h after harvesting), they were infected with
an appropriate titer of adenovirus in 1 ml medium 199. After 1 h,
without aspirating the adenoviral-containing medium, culture me-
dium was added back to the plates.
Cellular viability after adenoviral infection. 36 h after adenoviral
infection, the medium was aspirated and the plates were washed
twice with PBS. 1.5% glutaraldehyde in 50% PBS (19) was added to
the plates as a fixative. The number of rod-shaped or round myocytes
was counted at a magnification of 200. 20 fields per plate were
counted. Only myocytes fully visible within the field were counted.
Rod-shaped myocytes included those in which the length of the cell
was at least two times its width with an overall linear morphology.
Myocytes with mild end-plate changes were not excluded if the over-
all morphology met the above conditions. Only round myocytes that
were at least one-half the size of the average round myocyte in a field
were counted (to exclude cellular debris). To verify adenoviral infec-
tion in these experiments, transgene expression from concurrently in-
fected plates was demonstrated as described below.
b-Galactosidase expression. 36 h after adenoviral infection, cells
were fixed in 0.5% glutaraldehyde in 50% PBS for 5 min at room
temperature, and then stained with 10 mM K4Fe(CN)6, 10 mm
K3Fe(CN)6, 2 mM MgCl2, and 1 mg/ml X-gal (5-bromo-4-chloro-3-indo-
lyl-b-d galactopyranoside) (20) in PBS for 30 min at 378C. The stain-
ing solution was then aspirated and the cells were permanently fixed
in 1.5% glutaraldehyde in 50% PBS.
Immunoblotting. 36 h after adenoviral infection, cells were har-
vested in lysis buffer (5 mM Tris-HCl, pH 7.4, and 5 mM EDTA) and
Dounce homogenized with 10 strokes on ice. Samples were centri-
fuged 40,000 g to pellet membranes and supernatants were concen-
trated in a Centricon-10 (Amicon, Beverly, MA) at 5,000 g for 30 min
at 48C. The membrane fraction was resuspended in 75 mM Tris-HCl,
pH 7.4, 12.5 mM MgCl2, and 2 mM EDTA. Protein concentration was
determined by Bradford’s method (21). For detection of the Adeno-
bARKct transgene, 5 mg of the cytosolic extracts were electropho-
resed on a 12% SDS–polyacrylamide gel and transferred to a nitro-
cellulose membrane. As described in reference 17, a rabbit polyclonal
anti-serum that recognizes the carboxyl terminus of bARK was used
as a primary antibody and chemiluminescent detection was achieved
via an alkaline-phosphatase conjugated goat anti–rabbit IgG (Bio-
Rad, Hercules, CA). For detection of membrane G protein levels, 50
mg of the membrane fraction were loaded on 4–20% SDS/polyacryl-
amide denaturing protein gels and electrophoresed, followed by elec-
tro-transfer to nitrocellulose membranes. Primary polyclonal antise-
rum used at 1:2,000 dilution was anti-Gsa (sc-262; Santa Cruz
Biotechnology, Santa Cruz, CA) or anti-Gia3 (sc-823; Santa Cruz
Biotechnology). The anti-Gia3 does cross react with other Gia sub-
types. Standard chemiluminescent detection was achieved with an
ECL kit (Amersham Inc., Arlington Heights, IL).
Radioligand binding. Cells were harvested 36 h after adenoviral
infection and lysed as above. Nuclei were pelleted at 500 g. Crude
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membranes were prepared by centrifugation at 40,000 g and then re-
suspended in b-binding buffer (75 mM Tris-HCl, pH 7.4, 12.5 mM
MgCl2, and 2 mM EDTA). b-AR density was determined by incuba-
tion of membranes with a saturating concentration (z 300 pM) of
[125I] cyanopindolol (Dupont-NEN, Boston, MA) for 1 h at 378C as
described in reference 11 except that 10 mM alprenolol was used to
determine nonspecific binding. Specific binding was normalized to
membrane protein. To determine receptor affinity for CYP, satura-
tion isotherms were carried out with increasing concentrations of
[125I] cyanopindolol (9–360 pM) in the absence and presence of 10
mM alprenolol.
Intracellular cAMP assay. Cells were labeled overnight in 1.5
mCi/ml [3H]adenine (Dupont-NEN) in medium 199 and then preincu-
bated in MEM (GIBCO BRL) containing 10 mM Hepes (GIBCO
BRL) and 1 mM 3-isobutyl-1-methylxanthine (IBMX) (Sigma Chem-
ical Co.) for 30 min. Subsequently, the cells were stimulated with 10
mM (2)-isoproterenol (ISO) at 378C in medium containing 100 mM
ascorbic acid except in the ISO dose–response experiment where the
ISO concentration used is explicitly stated. In some experiments ei-
ther the selective b2 antagonist, 100 nM ICI 118, 551 (Research Bio-
chemicals International, Natick, MA) or the selective b1 antagonist, 1
mM ICI 89.406 (Cambridge Research Biochemicals, Wilmington,
DE) was included in the preincubation and stimulation steps. In an-
other series of experiments, myocytes were handled as above except
that they were stimulated for 5 min with 100 mM forskolin in the ab-
sence of ascorbic acid. The medium containing either ISO or forsko-
lin was aspirated at the designated time point and 1 ml of ice-cold
stop solution (2.5% perchloric acid, 100 mM cAMP, 10,000 cpm 14C)
was added to each well. cAMP was determined by anion exchange
chromatography and a percent incorporation of the total 3H uptake
into [3H]cAMP was calculated (22, 26). In some experiments, data
were standardized such that the percent conversion in control myo-
cytes (uninfected or Adeno-bGal–infected myocytes) was arbitrarily
set at one, and all other values were described as a relative amount of
cAMP to control.
Desensitization protocol. Myocytes were labeled as above except
10 mCi/ml of [3H]adenine was used. All media were prewarmed to
378C. For each condition described below, a percent conversion of to-
tal 3H to [3H]cAMP was determined (as in the intracellular cAMP as-
say). The myocytes were prestimulated either with MEM containing
no agonist (naive cells) or 10 mM ISO (prestimulated cells). This me-
dium was then aspirated at 10 min and each well was washed twice
with MEM. Medium with no additives was then added to half of the
naive cells (basal) and medium containing 10 mM ISO to the other
half of the naive cells (naive/stimulated). After 3 min the second incu-
bation was terminated by aspiration of medium and the addition of 1
ml of cold stop solution (see above). ISO-induced cAMP from naive
cells was calculated as ([naive/stimulated] 2 [basal]). The prestimu-
lated cells were handled in an analogous fashion; i.e., after prestimu-
lation, half were incubated for 3 min with medium only (prestimulated
only) and half were restimulated with 10 mM ISO (prestimulated/
restimulated). The incubation was terminated with aspiration and ad-
dition of cold stop solution. ISO-induced cAMP from prestimulated
cells was calculated as ([prestimulated/restimulated] 2 [prestimu-
lated only]). Desensitization was defined as the percent loss of activ-
ity due to prestimulation; i.e.,
Sarcolemmal adenylyl cyclase activity. 36 h after adenoviral in-
fection, membranes were prepared exactly as described above for ra-
dioligand binding, and protein concentration was measured. Adeny-
lyl cyclase activity was determined by incubating 25 mg of protein for
10 min at 378C with no agonist (basal) or in the presence of 100 mM
ISO, 100 mM zinterol, 10 mM NaF, or 100 mM forkolin. [a-32P]ATP
was isolated and cAMP quantitated as we have described in reference
Desensitization5
   1  – ISO-induced cAMP from prestimulated cellsISO-induced cAMP from naive cells-----------------------------------------------------------------------------------------------------------   100%×
12. For a determination of EC50, increasing concentrations (10
28 M
up to 1024 M) of ISO were incubated with sarcolemmal membranes
as above.
Data analysis. Data represent the mean6SEM. The isoprotere-
nol-cAMP dose–response curve was generated by GraphPad InPlot.
The isoproterenol-adenylyl cyclase dose–response curve was gener-
ated by GraphPad Prism. b-Adrenergic receptor affinity for CYP was
calculated using a nonlinear least squares fitting program (GraphPad
Prism). To compare the statistical significance of the differences be-
tween the means of two independent groups, the Student’s t test with
a two-tailed distribution was used. Calculations were done on Mi-
crosoft EXCEL.
Results
Cellular viability. In 20 fields, the mean number of myocytes
in the respective dishes was: uninfected 1,5376185; Adeno-
bARKct 1,5156208; or Adeno-b2AR infected 1,4776208 (n 5 3
plates, for each condition). Adenoviral infection did not alter
the percentage of rod-shaped myocytes (uninfected 6561%;
Adeno-bARKct 6262%; Adeno-b2AR 6461%). This con-
trasts with a marked decrease in the percentage of rod-shaped
myocytes after incubation with norepinephrine for 48 h as pre-
viously demonstrated by Mann et al. (23).
Expression of transgenes. The three adenoviral constructs
depicted in Fig. 1 were used in all infections and subsequent
experiments. Robust expression of each adenoviral transgene
was demonstrated after myocyte infection. As shown in Fig. 2
A, 36 h after infection with Adeno-bGal at a moi of 100 and
subsequent staining with X-gal, nearly all the myocytes stained
positive. Uninfected myocytes or those infected with Adeno-
b2AR or Adeno-bARKct remained colorless under these con-
ditions. Radioligand binding documented marked overexpres-
sion of b-ARs after infection with Adeno-b2AR (Fig. 2 B). A
dose-dependent effect is seen with increasing titers of Adeno-
b2AR that reaches a maximal receptor density (3,7006300
Figure 1. Diagram of recombinant adenoviral vectors. A first-genera-
tion adenoviral vector backbone (E1/E3 deletions) is ligated with the 
CMV promoter in front of the appropriate transgenes. Adeno-bGal 
contains the b-galactosidase marker gene, Adeno-b2AR the human 
b2AR, and Adeno-bARKct the 195–amino acid carboxyl terminus 
peptide fragment of bovine bARK1 described in reference 17. Ad-
eno-empty vector (not shown) contains no transgene. TR is the termi-
nal repeat of the adenoviral vector and E2/E3/E4 represent the re-
spective adenoviral genes. Full details of the construction of these 
vectors is given in the Methods section.
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Figure 2. Expression of recombinant adenoviral transgenes in adult rabbit 
ventricular myocytes. Myocytes were infected at a MOI of 100 for 36 h. (A) 
As assessed by X-gal staining, Adeno-bGal transduces z 100% of myocytes 
(right) compared to uninfected (Control) myocytes (left) or those infected 
with Adeno-b2AR or Adeno-bARKct. (B) Radioligand binding assays with 
[125I] iodocyanopindolol performed on crude membranes from Adeno-b2AR–
infected myocytes demonstrate a viral titer-dependent expression of b-adren-
ergic receptors. The data represent the mean6SEM of four independent ex-
periments, each performed in triplicate. (C) Protein immunoblots performed 
on cytosolic extracts from myocytes infected with the designated MOI of Ad-
eno-bARKct. 5 mg extracts were subjected to SDS–PAGE, probed with a 
bARK antiserum that recognizes the carboxyl terminus of bARK1, and de-
tected with an alkaline phosphatase-conjugated rabbit antiserum. The arrow 
on the left points to the expected size band of bARKct, the carboxyl terminus 
fragment of bARK1 described in reference 17. The arrows on the right depict 
the position of the molecular mass standards in kilodaltons.
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fmol/mg membrane protein) with a moi of 100. In contrast, in-
fection with either Adeno-bGal or Adeno-bARKct did not
significantly alter b-AR density (uninfected 165639; Adeno-
bGal 131623; Adeno-bARKct 134630 fmol/mg membrane
protein). There was no significant change in b-AR affinity for
CYP (Kd, dissociation constant) (Kd) after infection with Ad-
eno-b2AR (2668 pM) or Adeno-bARKct (3369 pM) versus
Adeno-bGal (31610 pM). Protein immunoblotting with anti-
serum raised against the carboxyl terminus of bARK1 demon-
strated expression of the novel, z 30-kD bARK peptide in
myocytes infected with Adeno-bARKct (Fig. 2 C). Increasing
titers of virus resulted in increased expression of protein with
maximal expression at a moi of 100. At a moi of one, a faint
band was seen in an overexposed blot (data not shown). As ex-
pected, cytosolic extracts from uninfected myocytes or those
infected with Adeno-bGal or Adeno-b2AR did not contain
this band under any conditions. As assessed by protein immu-
noblots of myocyte membranes prepared 36 h after infection,
transgene expression (b2AR or bARKct) did not alter levels
of Gs or Gi (data not shown).
Effect of transgenes on b-adrenergic signaling in intact myo-
cytes. As shown in Fig. 3 A, we first assessed the effect of in-
creasing titers of Adeno-bARKct on 10 mM ISO-stimulated
(30 min) intracellular cAMP levels. A moi of 50 led to near
maximal potentiation of response versus uninfected myocytes
(1961% vs. 661%, P , 0.001). This is concordant with the re-
Figure 4. Time course of cAMP accumulation after exposure to 10 
mM isoproterenol. Myocytes were infected with a moi 100 of Adeno-
bGal (s), Adeno-b2AR (n), or Adeno-bARKct (j) for 36 h and la-
beled overnight with 1.5 mCi/ml [3H]adenine. Intracellular cAMP was 
assayed as in Fig. 3. The maximum percent conversion of total 3H up-
take to cAMP in Adeno-bGal–infected myocytes (5.761%) is arbi-
trarily set at one, and all other data are expressed as relative values.
with Adeno-bGal (moi 5,000) or Adeno-empty vector (moi 1,000) 
had no effect on cAMP accumulation after 15 min of ISO stimulation 
(data not shown). The data represent the mean6SEM of three (A) or 
four to five (B) independent experiments, each performed in tripli-
cate. fP , 0.05, *P , 0.01 vs. uninfected myocytes.
Figure 3. Isoproterenol-induced cAMP levels in Adeno-bARKct–
infected myocytes. Experiments were performed 36 h after adenovi-
ral infection. Myocytes are labeled overnight with 1.5 mCi/ml [3H]ad-
enine, and preincubated for 30 min with IBMX. The accumulation of 
intracellular cAMP following ISO stimulation at 378C is expressed as 
a percent conversion from total 3H uptake. Shown is the effect of in-
creasing moi of Adeno-bARKct (A) or increasing concentration of 
ISO (B). In A, myocytes were stimulated with 10 mM ISO for 30 min. 
In B, myocytes were infected with a moi 100 of Adeno-bGal (s) or 
Adeno-bARKct (j) and stimulated with the designated concentra-
tion of ISO for 20 min. In B, the basal values were determined from 
myocytes labeled with 10 mCi/ml [3H]adenine in preliminary experi-
ments designed specifically to assess basal activity (n 5 5). Infection 
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lationship of adenoviral titer and production of transgene pro-
tein (Fig. 2 C). In contrast, myocytes that are uninfected, Ad-
eno-bGal infected (moi up to 5,000), or Adeno-empty vector
infected (moi 1,000) accumulate a nearly identical amount of
cAMP following 15 min of ISO stimulation (data not shown).
An ISO dose–response curve done in myocytes infected with a
moi 100 of either Adeno-bGal or Adeno-bARKct (Fig. 3 B)
also shows potentiation of b-AR signaling by Adeno-bARKct.
After 20 min of stimulation with increasing concentrations of
ISO, an increased Vmax was seen in Adeno-bARKct–infected
myocytes (1261%) as compared to Adeno-bGal–infected my-
ocytes (5.460.5%, P , 0.05) as well as an approximately four
fold leftward shift in the EC50 (100 nM Adeno-bGal vs. 28 nM
Adeno-bARKct).
To further assess the effect of Adeno-bARKct or Adeno-
b2AR infection on the b-AR system, a time course of cAMP
accumulation in response to ISO was conducted (Fig. 4). Basal
cAMP level in Adeno-bGal–infected myocytes (0.1%) was un-
changed by infection with Adeno-b2AR (0.160.1%) or Ad-
eno-bARKct (0.1%). However, ISO-stimulated cAMP accu-
mulation is increased at 5, 15, and 30 min after ISO versus
control in myocytes infected with Adeno-b2AR (1.660.1-,
1.560.1-, and 2.260.1-fold) or Adeno-bARKct (2.860.4-,
2.760.1-, and 3.360.2-fold). In contrast, forskolin-stimulated
cAMP accumulation is not significantly enhanced versus con-
trol (22% conversion to cAMP) after infection with Adeno-
b2AR (1.260.1-fold, n 5 5) or Adeno-bARKct (1.360.2-fold,
n 5 6). The rate of accumulation of cAMP following ISO stim-
ulation in Adeno-bGal myocytes rapidly diminishes such that
from 15 to 30 min it has essentially plateaued (Fig. 4). In
marked contrast, during this time interval (15–30 min) Adeno-
bARKct–infected myocytes continue to accumulate significant
rates of cAMP (0.05 relative cAMP U/min), comparable to the
maximal rates seen in control myocytes (0.06 relative cAMP
U/min during the interval 0–15 min). The prolongation of re-
sponse to agonist after Adeno-bARKct infection is consistent
with an acquired defect in desensitization.
Quantification of this desensitization defect is shown in Fig.
5. After prestimulation with 10 mM ISO for 10 min, desensiti-
zation is significantly inhibited in Adeno-bARKct–infected
cells as compared to Adeno-bGal–infected cells (P , 0.001,
n 5 4). Nearly identical data were obtained following a 3 min
prestimulation with 10 mM ISO (data not shown). Uninfected
myocytes exhibited nearly the same level of desensitization
(35%) as Adeno-bGal–infected cells (n 5 2) after a 10 min
prestimulation with 10 mM ISO.
Because the myocardium contains both b1 and b2 adrener-
gic receptors, we used selective antagonists to determine which
receptor subtype would be affected by bARKct expression
(Fig. 6). As previously shown in cultured myocytes (24), the
b1AR is the predominant mediator of ISO-induced cAMP ac-
Figure 5. Desensitization in Adeno-bGal versus Adeno-bARKct–
infected myocytes. ISO-induced cAMP accumulation was assayed as 
in Fig. 3 and was measured 36 h after infection with a MOI 100 of ei-
ther Adeno-bGal (Control) or Adeno-bARKct. To quantify desensi-
tization, a prestimulation–restimulation approach was used in which 
cells were initially treated with or without agonist (10 mM ISO) for 10 
min (prestimulated myocytes or naive myocytes, respectively). The 
response to a subsequent 3 min stimulation with 10 mM ISO was com-
pared. Desensitization, the percent loss of activity due to prestimula-
tion (see Methods for calculations) was 3761% in Adeno-bGal 
(Control) myocytes (gray bar) and 1662% in Adeno-bARKct myo-
cytes (black bar). Data are the mean6SEM of four independent ex-
periments, each in triplicate. Desensitization in Adeno-bGal infected 
myocytes was not significantly different than in uninfected myocytes 
(n 5 2, data not shown). *P , 0.01.
Figure 6. Effect of b1 (ICI 89.406) or b2 (ICI 118, 551) selective an-
tagonists on ISO-induced cAMP levels. Myocytes were infected with 
a moi 100 of Adeno-bGal (left), Adeno-b2AR (middle), or Adeno-
bARKct (right) for 36 h. Intracellular cAMP was assayed after a 20 
min stimulation with 10 mM ISO at 378C in the absence of antagonists 
(white bars) and in the presence of ICI 118, 551, a selective b2AR an-
tagonist (gray bars) or ICI 89.406, a selective b1AR antagonist (black 
bars). The percent conversion of total 3H uptake to [3H]cAMP after 
ISO stimulation in Adeno-bGAl–infected myocytes (5.461%) is ar-
bitrarily set at one (left, white bar), and all other data are expressed as 
relative values. Data represent the mean6SEM of three (ICI 89.406), 
four (ICI 188,551), or five (no antagonist) independent experiments, 
each in triplicate. *P , 0.05 vs. Adeno-bGal no antagonist, DP , 0.05 
vs. Adeno-b2AR no antagonist, 
FP , 0.01 vs. Adeno-bARKct no an-
tagonist.
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cumulation. Thus, in Adeno-bGal–infected (control) myo-
cytes, the response to ISO is only minimally affected by ICI
118,551, a b2AR selective antagonist (bGal, gray bar) but is
significantly inhibited by ICI 89.406, a b1AR selective antago-
nist (bGal, black bar). After infection with Adeno-b2AR,
there is a 1.960.2-fold potentiation of ISO-induced cAMP lev-
els (b2AR, white bar). ICI 118, 551 reduces the accumulation of
cAMP back to control levels, presumably by blocking exoge-
nous b2ARs (b2AR, gray bar). This experiment demonstrates
that 100 nM ICI 118,551 effectively blocks the b2AR-mediated
response. Since the same concentration of ICI 118,551 has little
effect on diminishing the cAMP response in Adeno-bARKct–
infected cells (bARKct, gray bar), this strongly suggests that
the enhanced cAMP accumulation following bARKct expres-
sion is mediated via b1ARs. Supporting this hypothesis is the
effect of ICI 89.406, the b1AR antagonist, which effectively at-
tenuates this signal (bARKct, black bar).
Effect of transgenes on b-adrenergic signaling in myocyte
sarcolemmal membranes. Adeno-b2AR infection significantly
increased both basal cyclase activity (53.663.2 pmol cAMP/
mg/min) versus control (Adeno-bGal, 36.963.1 pmol/mg/min,
P , 0.005) and ISO-stimulated cyclase (10466.7 pmol cAMP/
mg/min) versus control (63.464.8 pmol/mg/min, P , 0.005)
(Table I). Consistent with this effect being mediated through
the b2AR, the stimulation of adenylyl cyclase by zinterol, a se-
lective b2AR agonist, is also significantly increased in Adeno-
b2AR–infected myocytes (98.267.5 pmol cAMP/mg/min) ver-
sus control (4864 pmol/mg/min, P , 0.005). This potentiation
of b-adrenergic signaling does not appear to be secondary to
changes in either G proteins or adenylyl cyclase as the re-
sponse to NaF or Forskolin is unchanged by Adeno-b2AR in-
fection (Table I). An ISO–adenylyl cyclase dose–response
curve did not show significantly enhanced agonist potency
(EC50) after Adeno-b2AR infection (48 nM) versus control
(59 nM).
Similar to that demonstrated in transgenic mice (12), the
Adeno-bARKct transgene does not enhance b-adrenergic ag-
onist stimulation (either ISO or zinterol) of membrane adeny-
lyl cyclase versus control. This result is expected since bARKct
is a cytosolic peptide that is not present in the membrane frac-
tion (12). Infection with Adeno-bARKct also does not affect
the response of membrane adenylyl cyclase to NaF or forsko-
lin as compared to control.
Discussion
A number of alterations in the myocardial b-adrenergic path-
way occur in patients with congestive heart failure including
downregulation of b1ARs (8, 9, 25), uncoupling of the remain-
ing b-ARs from adenylyl cyclase (7), and increased expression
of bARK1 (9, 10), an enzyme that phosphorylates and uncou-
ples only agonist-bound receptors (26) including the b1AR (27,
28). Our laboratory has been studying the feasibility of revers-
ing these alterations in the b-adrenergic cascade to restore car-
diac inotropy to normal in patients with depressed systolic
function. Transgenic mice that overexpress the human b2AR
under control of the cardiac specific a-myosin heavy chain pro-
moter have a basal cardiac inotropy that rivals that achieved in
wild-type mice after maximal ISO stimulation (11). Likewise,
transgenic mice with cardiac overexpression of an inhibitor of
bARK (bARKct) have increased basal contractility and an en-
hanced response to ISO (12).
Having established that cardiac function can be enhanced
in transgenic mice by overexpression of either b2ARs or an in-
hibitor of bARK, we are now attempting to use recombinant
adenovirus encoding these transgenes to potentiate b-adrener-
gic signaling. This paper is the initial report of these efforts us-
ing a cell culture model consisting of adult rabbit ventricular
myocytes. The relevance of a primary cardiomyocyte culture
model is highlighted by the demonstration that isolated myo-
cytes from human patients with CHF have demonstrable defi-
ciencies in response to b-agonist stimulation (29). As others
have shown (20, 30), we have found adenovirus to achieve
z 100% transduction efficiency as assessed by X-gal staining
(Fig. 2 A). We also have demonstrated robust transgene ex-
pression after infection with Adeno-b2AR as assessed by radi-
oligand binding (Fig. 2 B) and Adeno-bARKct by protein im-
munoblots (Fig. 2 C). As has been seen previously with
chloramphenicol acetyltransferase or b-galactosidase (20, 30),
expression of both the b2AR and bARKct transgenes is de-
pendent upon viral titer, and with our vector reaches a maxi-
mum at a moi between 50 and 100.
After adenoviral infection, b-adrenergic signaling was as-
sessed by the accumulation of intracellular cAMP in the intact
myocyte or by activation of adenylyl cyclase in sarcolemmal
membranes. Infection with Adeno-b2AR potentiated the
b-adrenergic signal as assessed both by the intracellular cAMP
response (Fig. 4) and by membrane adenylyl cyclase activity
(Table I). Evidence that the potentiated signal following Ad-
eno-b2AR infection is mediated via b2-adrenergic receptors in-
cludes the inhibition of the increased ISO-stimulated cAMP
response by a selective b2-adrenergic antagonist (Fig. 6) and
the significantly increased stimulation of cyclase activity versus
control by zinterol, a selective b2-adrenergic agonist (Table I).
While it might have been expected that the EC50 for isoproter-
enol stimulation of adenylyl cyclase would have been left
shifted after b2-adrenergic receptor overexpression, this was
not observed. This most likely relates to the relatively modest
overexpression of receptors in these experiments. In myocar-
dial membranes from transgenic animals expressing very high
concentrations of receptors (20–40 pmol/mg) (11), a 10-fold
shift was observed. In animals expressing z 1.2 pmol/mg,
about a fourfold shift was found (31). By contrast, in the iso-
lated myocytes used for the experiments in which we deter-
mined EC50’s for isoproterenol, only z 600 fmol/mg of b2-
adrenergic receptors were present.
Infection with Adeno-bARKct also potentiated b-adrener-
gic signaling in the intact myocyte, but its effect was mediated
via the b1-adrenergic receptor (Fig. 6). Notably, Adeno-
bARKct infection does not affect b-adrenergic stimulation as
assessed by membrane adenylyl cyclase activity (Table I).
Table I. Adenylyl Cyclase Activity in Sarcolemmal Membranes 
from Adenoviral-infected Adult Rabbit Ventricular Myocytes
Basal
Isoproterenol
(100 mM)
Zinterol
(100 mM)
NaF
(10 mM)
Forskolin
(100 mM)
Adeno-bGal 36.963.1 63.464.8 48.064.0 12069.5 223613.6
Adeno-b2AR 53.663.2* 10466.7* 98.267.5* 12268.2 202616.2
Adeno-bARKct 41.364.4 73.868.8 58.468.0 121611 205613.9
Data represent pmol cAMP/mg protein/min6SEM, n 5 325 cell isola-
tions, assays done in duplicate. *P , 0.005 vs. Adeno-bGal.
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These results are in agreement with previously published data
from transgenic mice that overexpress the identical transgene
and are to be expected because bARKct is a cytosolic peptide
that is not present in the membrane fraction (12). Further-
more, these data strongly suggest that the potentiation of b1-
adrenergic signaling by Adeno-bARKct in the intact myocyte
is not secondary to a change in expression of a membrane com-
ponent of the b-adrenergic cascade (e.g., G proteins or adeny-
lyl cyclase) in which case enhanced b-adrenergic stimulation of
sarcolemmal adenylyl cyclase also should have been seen.
As predicted, the mechanism of potentiation of b1AR sig-
naling by Adeno-bARKct involves inhibition of receptor de-
sensitization. bARKct is a 195–amino acid carboxyl terminus
peptide fragment of bovine bARK1 that contains the Gbg
binding domain. It presumably sequesters dissociated Gbg, pre-
venting it from recruiting bARK1 to the membrane, and thus
inhibits bARK phosphorylation of its activated receptor sub-
strate. These actions of the carboxyl terminal peptide of
bARK1 have been well characterized previously in vitro (17,
32, 33). In this study, Adeno-bARKct inhibition of desensitiza-
tion was documented in two ways. In a time course experiment
of cAMP accumulation following ISO stimulation, the ability of
myocytes infected with Adeno-bARKct to respond to ISO per-
sisted far longer than in the control myocytes (Fig. 4). In a sec-
ond set of experiments, using a prestimulation–restimulation
approach to quantitate desensitization, Adeno-bARKct infec-
tion was again shown to significantly inhibit this process (Fig.
5). Because individual cell types have different mechanisms of
desensitization (34), these experiments are informative by
showing that in rabbit ventricular myocytes Gbg activation of
bARK plays a central role in desensitization of the b1AR.
Several other potential mechanisms for the enhanced b-adren-
ergic signal after infection with Adeno-b2AR or Adeno-bARKct
were excluded. Unlike a prior report based on neonatal myo-
cytes (35), adenoviral infection did not enhance b-adrenergic
signaling per se since there was no difference in the amount of
ISO-stimulated cAMP between uninfected myocytes and
those infected with high titers of Adeno-bGal or Adeno-
empty vector. Adeno-b2AR or Adeno-bARKct infection did
not significantly affect levels of G proteins as determined by
protein immunoblots and by the adenylyl cyclase response af-
ter NaF stimulation, nor did the transgenes significantly in-
crease levels of adenylyl cyclase as assessed by its response to
forskolin stimulation (Table I). As expected, Adeno-bARKct
also did not increase expression of the b-adrenergic receptor.
In conclusion, recombinant adenoviral infection leading to
overexpression of the b2AR or an inhibitor of bARK-medi-
ated desensitization can potentiate b-adrenergic signaling in
cultured adult rabbit ventricular myocytes. We emphasize that
large hurdles remain before genetic modulation of the b-adren-
ergic system can be considered a potential therapy for patients
with systolic dysfunction. These hurdles include extending the
limited duration of expression of recombinant adenoviral
transgenes (36), obtaining global myocardial delivery of the
adenovirus presumably via coronary artery injection (37), and
demonstrating a hemodynamic and survival benefit in animal
models of CHF.
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